A
AngioInsight
Enables cardiologists to realize the full value of anatomical and physiological diagnostics to augment clinical decisions, improve patient outcomes and reduce cost for the treatment of coronary artery…
About AngioInsight
AngioInsight leverages artificial intelligence and computational modeling to transform the care of coronary artery disease. The company provides cardiologists with advanced tools to quantify stenosis severity and non-invasively determine Fractional Flow Reserve (FFR) within the cardiac catheterization lab. This enables more accurate and timely clinical decisions, ultimately improving patient outcomes and reducing treatment costs. AngioInsight primarily serves cardiologists and healthcare institutions focused on coronary artery disease, operating within the medical technology and healthcare sectors. The business model revolves around offering its diagnostic solutions as a service, generating revenue through subscriptions and usage fees. By integrating cutting-edge AI and computational techniques, AngioInsight aims to set a new standard in cardiac care.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2018
- Headquarters
- Minnetonka, United States
- Employees
- 19
- Open positions
- None listed
- Dealroom signal
- 43.8/100
- Industry
- Health
- Sub-industry
- Medical Devices
- Sector
- Health Tech & Medtech, Medical Imaging, Hard Tech
- Technology
- Artificial Intelligence
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Oct 2025 | $25M | $100M | Undisclosed | ↗ |
| SEED✓Equity / VC | Apr 2025 | — | — | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for AngioInsight is 1.4K monthly website visits, up 66.7% over the last three months. AngioInsight's team grew 5.6% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
US National Science Foundation
Other known investors2 additional known investors
Accelerate Blue Fund
Avestria Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about AngioInsight on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See AngioInsight’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.






